-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sophia Antipolis, France-August 23, 2021: According to the latest breakthrough research presented at the 2021.
Dr.
Atrial fibrillation (AF) is an arrhythmia that causes the heart to beat faster and irregularly
It is recommended that patients with coronary heart disease and heart failure take exercise-based rehabilitation, but there are few studies on the benefits of atrial fibrillation
The ACTIVE-AF trial evaluated the effects of a 6-month exercise plan combined with supervision and home aerobic exercise on AF recurrence and symptom severity-during the intervention period and the subsequent 6-month follow-up
The trial randomly assigned 120 symptomatic patients with atrial fibrillation for 6 months of exercise intervention or routine care
The common main result is the severity score of atrial fibrillation symptoms and the proportion of patients with atrial fibrillation recurrence at 12 months
The average age of the patients in the study was 65 years old, and 43% of them were women
Compared with the control group, the patients in the exercise group also had a significant reduction in the severity of symptoms at 12 months
He concluded: "Our research provides evidence that aerobic exercise should be included in the treatment of patients with symptomatic atrial fibrillation
Original reference:
1 Abstract title: An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomised controlled trial.
2 Chugh SS, Havmoeller R, Narayanan K, et al .
3 Staerk L, Wang B, Preis SR, et al .
4 Pathak RK, Elliott A, Middeldorp ME, et al .
5 Malmo V, Nes BM, Amundsen BH, et al .